In-Silico Model for Predicting CYP2D6-Mediated Drug-Drug Interactions.

CONCLUSIONS: According to our results, knowledge of the inhibition constant and therapeutic range (or its plasma levels if disponible) of the inhibitor would be sufficient to determine the intensity and clinical relevance of a CYP2D6-mediated DDI. PMID: 32379594 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32379594?dopt=Abstract

Source: Current Clinical Pharmacology - May 6, 2020 Category: Drugs & Pharmacology Authors: Lozano R, Frutos A, Martinez A Tags: Curr Clin Pharmacol Source Type: research

More News: Drugs & Pharmacology